Topical Micronutrient Products by Darlene McCord
PART III

David E. Davenport, M.D., FACR
Darlene McCord, Ph.D., FAPWCA
Brenda Bull R.T. (R)(T)

ONS Skin Evaluation Results

The study results found that Remedy products performed 14.4% better than the SOC. Furthermore, the incidence of wet desquamation was 25% less in the Remedy treatment group. Significantly, over 10% of the patients receiving the SOC sustained infections during the course of their radiotherapy and one patient had to discontinue care. No infections or discontinuation of care were reported in the Remedy group. Further, 46% of the Remedy patients reported no reduction in their quality of life due to skin related problems including product application values, resulting in higher rates of skin care compliance.

Patient Quality of Life

Establishing a treatment protocol for radiation dermatitis is of importance and should take into account patient QL. The current international QL criterion for patients receiving skin care is based on the validated Dermatology Life Quality Index (vDLQI) developed by Andrew Y. Finlay, M.D. The vDLQI is the dermatology industry standard for measuring QL. The vDLQI has been sited in more than 130 published articles and abstracts, in 17 countries and 21 languages.